Delavirdine (DLV), a non-nucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, was evaluated in two-and three-drug combination regimens with lamivudine (3TC) and zidovudine (ZDV). The effect of continuous drug treatment on HIV-1JR-CSF replication in human peripheral blood mononuclear cells was measured by an ELISA for p24 core antigen. Drug synergy, estimated by the combination index method and the method of Pritchard & Shipman, was observed when DLV was combined with 3TC over a range of drug concentrations (DLV at 1, 3, 10, 30 and 100 nM; 3TC at 3, 10,30, 100 and 300 nM). Two-drug combinations of ZDV and DLV at a 1:3 ratio or ZDV and 3TC at a 1:10 ratio were synergistic at greater than 75% inhibition levels. Three-drug combinations of ZDV, DLV and 3TC (ZDV at 0.3, 1,3 and 10 nM; DLV at 1, 3, 10 and 30 nM; 3TC at 3, 10,30 and 100 nM) at the ratio of 1:3:10 also yielded significant synergistic effects. None of the combinations studied showed significant additive or synergistic drug toxicity. These in vitro data suggest that DLV should be evaluated in two-and three-drug combinations with 3TC and ZDV in clinical trials.
Introduction
A major drawback of therapy with a single antiviral agent against human immunodeficiency virus type 1 (HIV-1) is the selection of pre-existing drug-resistant virus from the large population of genetic variants present in HIV-1infected individuals (vonBriesen et al, 1987; Goodenow et al., 1989; Najera et al., 1995) . Historically, combination chemotherapy has been used successfully to overcome drug resistance associated with the treatment of cancer and certain bacterial infections such as tuberculosis (Frei, 1991; Ritter et al., 1995) . Similarly, much attention in HIV-1 therapy has been directed to the study of treatment approaches employing a combination of drugs. In various in vitro studies, combinations of two or more antiretroviral agents have shown synergistic inhibition of virus replication (De Clercq, 1994a,b; Johnston & Hoth, 1993; Lange, 1995; Merigan, 1991) . In clinical studies, the combined use of drugs in patients with AIDS has often shown greater and more prolonged improvement in markers of disease severity such as CD4+ cell counts and viral titres in plasma (Ruiz et al, 1996 ; D Mathez, P Bagnarelli, P DeTruchis, I Gorin, C Katlama, G Pialoux, C Ruggeri, AG Saimot, R Tubiana, JP Chauvin, M Clementl & J Leibowitch. A triple combination ofritonavir, AZT, DDC as a first line treatment of patients with AIDS: update. XI International Conference on AIDS, Vancouver, Canada, 7-12 July, 1996. Abstract Mo.B.175) . This improvement in clinical efficacy may be attributed to additive or synergistic drug interactions, although other factors may also be involved. Thus, there is general agreement between the in vivo results from clinical trials and the in vitro studies regarding the merits of combination drug therapy. This suggests that it is important to evaluate a potential drug candidate in combination with other agents in HIV-1infected cell cultures.
(-)~-L-2' ,3'-Dideoxy-3'-thiacytidine (lamivudine; 3TC), a recently approved nucleoside inhibitor of HIV-1 reverse transcriptase (RT), has been shown to select rapidly for resistant virus both in vitro (Schinazi et al, 1993; Tisdale et al., 1993) and in vivo (Kavlick et al., 1995; Schuurman et al., 1995) . When used in comb ina-tion with 3'-azido-3'-deoxythymidine (zidovudinc; ZDV), 3TC-resistant viral populations still emerged, but significantly improved efficacy was observed in patients with AlDS (Kuritzkes et al., 1996) . Although the cause of this enhanced efficacy is unclear, it has been shown that viral resistance to 3TC can be associated with suppression of resistance to ZDV . However, viral strains resistant to both these compounds have been selected in cell cultures (Goulden eta!., 1996) . This suggests that it might be possible to improve further the long-term efficacy of combined 3TC and ZDV by including a third inhibitor from a different class. Examples of such a combination that have shown outstanding efficacy are treatment regimens employing a protease inhibitor in' combination with two RT inhibitors [R Gulick, J Mellors, D Havlir, J Eron, C Gonzalez, D McMahon, D Richman, F Valentine, L Jonas, A Meibohm, R Chiou, P Deutsch, E Emini &J Chodakewitz, Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC). Third Conference on Retroviruses and Opportunistic Infections, Washington, D.C., 28 January-1 February, 1996. Abstract #LB7; D Mathez, P Bagnarelli, P DeTruchis, I Gorin, C KatIama, G Pialoux, C Ruggeri, AG Saimot, R Tubiana, JP Chauvin, M Clementi & J Leibowitch. A triple combination of ritonavir, AZT, DDC as a first line treatment of patients with AIDS: update. XI International Conference on AIDS, Vancouver, Canada, 7-12 July, 1996. Abstract Mo.B.175] . With the recent approval of three peptide-derived protease inhibitors (saquinavir, ritonavir and indinavir), such a combination regimen is now available for clinical use (Chong, 1996) .
The non-nucleoside RT inhibitors (NNRTIs), such as 1-(5-methanesulphonamido-1H-indol-2-yl-carbonyl)-4-[3 -(l-methylethylamino )pyridinyl]piperazine monomethane sulphonate (delavirdine; DLV), loviride and nevirapine, represent another class of agents that may enhance the efficacyof nucleoside RT inhibitors (NRTIs). Currently, nevirapine is approved by the FDA for combination therapy with RT inhibitors, whereas DLV is in advanced stages of clinical trials. In addition to synergistic drug interactions (De Clercq, 1994a,b) and the ability to inhibit completely viral replication in cultures (Balzarini et a!., 1993) , the combination ofNNRTIs with NRTIs may also suppress or reduce the emergence of drug-resistant virus strains in vitro (Larder, 1992; Balzarini et a!., 1996) . For example, Larder (1992) reported that drug resistance to a NNRTI in combination with ZDV is associated with restoration of drug susceptibility to ZDV. These results suggest that further studies are needed using combinations of NNRTIs with NRTIs.
We have previously reported that DLV is synergistic when used in two-drug combinations in vitro with NRTIs 334 ZDV or 4-amino-1-p-D-2',3'-dideoxyribofuranosyl-2-(lH)-pyrimidinone (zalcitabine; ddC), and in three-drug combination involving ZDV and 2',3'-dideoxyinosine (didanosine; ddI) (Chong et al., 1994; Chong & Pagano, 1997) . Here we describe and compare the antiviral effects of two-and three-drug combinations of DLV, 3TC and ZDV in acutely infected peripheral blood mononuclear cells (PBMC).
Materials and Experimental Procedures
Compounds 3TC (Glaxo-Wellcome), ZDV (Sigma) and DLV (Pharmacia & Upjohn) were prepared as 10 mM stocks in DMSO and maintained at -70 DC.
Virus
HIV-1JR_CSF (I Chen) was obtained through the AlDS Research and Reference Reagent Program (Division of AlDS, NIAlD, NIH, USA). HIV-1 JR _ CSF was selected because it replicates in PBMC but has not been adapted to replicate in cell lines (Koyanagi et a!., 1987) . Stock viruses ofHIV-1JR_CSF were harvested as culture supernatant from infected primary human PBMC culture as previously described (Chong et a!., 1994) .
Antiviral assay
Human PBMC were obtained from fresh plasmapheresis preparations taken from HIV-1-seronegative donors and prepared by density gradient centrifugation with Ficoll-Hypaque (Organon Teknika, Durham, N.C., USA). PBMC were collected, washed and incubated for 3 days in culture medium containing 4 ug mL-1 phytohaemagglutinin (PHA-P). PHA-treated cells were then cultured in assay medium containing recombinant human interleukin 2 (80 units mL-l; Gibco). Under our experimental conditions and without change of culture media, uninfected PBMC reached a peak cell number (1.85x10 6 cells mL-1) and showed >95% survival on day 5 after seeding. PBMC were infected with HIV-1JR_CSF at an m.o.i. of 0.005. After five days of incubation, culture supernatant showed a mean p24 concentration of 200 ng mL-1 as measured by ELISA (Coulter Diagnostics, Hialeah, Fla., USA). This is equivalent to 70% of the peak viral titre achievable on day 7 post-infection. PBMC antiviral assays were set up as described previously (Chong et a!., 1994) . The percentage inhibition of HIV replication on day 5 of treatment was determined by comparing HIV p24 antigen levels in the supernatant of infected cells treated with inhibitor versus supernatant from the control cultures without compound. The levels ofDMSO in culture medium containing drugs were less than 0.01% for all drug concentrations tested. In previous studies, we have shown r that up to 0.03% DMSO had no effect on viable cell number or viral p24 production.
Combination studies
The inhibition of HlV-1 replication by combinations of DLV, 3TC and ZDV was evaluated in experiments involving several molar ratios of the drugs. For a two-drug combination of DLV and 3TC, four or five concentrations of each drug (DLV at 1, 3, 10, 30 and 100 nM; 3TC at 3, 10, 30, 100 and 300 nM) were titrated in duplicate wells in a checkerboard manner. For three-drug combination studies, four or five concentrations of each drug (DLV at 1, 3, 10, 30 and 100 nM; 3TC at 3, 10, 30, 100 and 300 nM; ZDV at 0.3, 1, 3, 10 and 30 nM) or drug combinations were assayed in triplicate wells. For each molar ratio, three to four datapoints were analysed for combination indices (Cl) by the multiple drug effect equation of Chou & Talalay (1984) using the more conservative mutually non-exclusive drug interaction condition. The Cl values at various fractional inhibitions (50, 75, 95 and 99%) were used to determine whether the combinations were synergistic (Cl<1), additive (Clel.) or antagonistic (Cl> 1). For our studies, we considered a Cl Combinotion of DLV with 3TC and ZDV range of 0.9-1.1 as an additive effect, in accordance with the suggested guidelines of the computer program we used. Estimates of accuracy of Cl were calculated with Monte Carlo simulations (Belen'kii & Schinazi, 1994) and were computed using a new Windows-based software program for dose-effect analysis called Calcusyn (Biosoft, Cambridge, UK). The 95% confidence interval at each level of Fa is calculated by the formula: CI±(1.96xSD), where the values Cl+(1.96xSD) and Cl-(1.96xSD) correspond to the upper and lower boundaries of the confidence interval, respectively. With the MacSynergy program, the theoretical additive interactions from single-drugtreated groups were plotted as a plane in a three-dimensional graph. The data obtained from combination assays were then compared with the predicted additive interaction. Values above the additive plane represent synergistic interactions, while values below the plane represent antagonism. The extent of drug synergy is determined by the volume of the area above the additive plane. According to Prichard et al. (1993) values of synergy of between 25 and 50 IlM2% are considered minor but significant, whereas values between 50 and 100 IlM2% indicate moderate synergy and may be important in vivo.~I 
Assay of cytotoxicity
The cytotoxicities of the compounds in uninfected PEMC cultures were evaluated by measuring the formation of formazan, a tetrazolium dye, in a 3-(4,5-dimethylthiazoyl-2-yl)-2,5-diphenyltetrazolium bromide (MIT; Sigma) assay as described previously (Mossman, 1983) . Cytotoxicity assays were performed by incubating uninfected cells in the presence of various concentrations of the drugs tested individually and in combination for 5 days under similar conditions to the antiviral assays.
interactions in the subsequent combined therapy experiments under similar assay conditions.
Effects of DLV and 3TC combinations
We studied the effects of combinations ofDLV and 3TC on HIV-1 replication while monitoring the potential cytotoxicity of these agents to PEMC. Combination of Percentage synergy was computed from the mean percentage inhibition of three experiments (Table 1) ; the height of the bars indicates amount of synergy.
Results

Effects of DLV, 3TC or ZDV alone on HIV replication in PBMC
We first determined the antiviral effect ofDLV in comparison to 3TC and ZDV in acutely infected PEMC. In human PEMC cultures acutely infected with the clinical isolate HIV-1 JR _ CSF ' DLV showed a dose-dependent inhibition of HIV-1 with IC so and IC gO values in the range of 5-12 and 20--50 nM, respectively. In similar assays, 3TC showed rc., and IC gO values in the range of 60--130 and 300--350 nM, respectively, and ZDV showed IC so and IC gO ranges of3-l0 and 16-25 nM, respectively. We also determined the toxicity of these compounds to the cell type used in this study.DLV, 3TC and ZDV only showed 50% cytotoxicity at concentrations greater than 100 flM in PEMC cultures (data not shown). From the data, concentration ranges of DLV, 3TC and ZDV were selected that would best demonstrate drug p DLV and 3TC over the range of concentrations tested was consistently more effective than either agent alone (Table 1 ). The data from each combination tested were analysed by the methods of Chou & Talalay (1984) and Prichard et al. (1993) . For computation of Cl, the dose-effect for each single agent and the combinations were used to make a series of median effect plots. From these plots, Cl values at combination ratios of DLV to 3TC of 1:1, 1:3 and 1:10 were computed, because DLV was about three-to 10-fold more active than 3TC on a molar basis. These ratios allowed the two compounds to be used together in the assays to achieve the widest activity range. Synergistic interactions at these molar ratios were observed with Cl<1 at 50, 75, 90 and 95% inhibition levels (Table 2 , mean of three experiments).
Combination of DLV with 3TC and ZDV
According to the method of Prichard et at. (1993), combinations of DLV and 3TC were also synergistic with a volume of synergy of 79.2 IlM2% at the 95% confidence levels (Fig. 1) . Thus, both methods suggested that combination of DLV and 3TC yielded moderate levels of synergy.
. We observed no anti-proliferative activity or toxicity to cultured cells with either of these single agents or their combinations (DLV at 30, 100, 300 nMj 3TC at 100, 300, 1000 nM). Thus, the enhanced antiviral activity observed was associated with the specific antiviral effects of the combined agents. The toxic concentrations of these agents were 100-fold greater than the concentrations used in the combination experiments. 
Effect of a three-drug combination of DLV, 3TC
and ZDV We performed two larger experiments in which DLV, 3TC and ZDV were evaluated alone and as two-and three-drug combinations in acutely infected PBMC. By testing the individual drugs and their combinations under identical assay conditions, we could more accurately evaluate the antiviral effect of the combination of three drugs compared to the combination involving two drugs. Table 3 shows the dose-effect for each single agent across the concentration ranges used in the subsequent combination experiments. The two-drug combinations of DLV plus ZDV, 3TC plus ZDV and DLV plus 3TC were more suppressive than the corresponding drugs used alone. With ZDVas a component in the combined regimens, we observed greater antiviral effects than with 3TC and DLV combined. This is because the concentrations of ZDV used in the study were more inhibitory than DLV or 3TC as single agents (Table 3) . Both two-and three-drug combination groups showed more than 90% inhibition of virus growth at the highest drug levels tested (Table 3) . However, at lower drug levels, these groups showed significant differences in the extent of viral inhibition as reflected by the production of p24 core antigen (Table 4 ). The two-drug combination groups were significantly less effective (P<O.Ol) at inhibiting viral replication than the three-drug combination groups at the drug levels analysed. We also compared the extent of viral inhibition between the two-drug and single-drug groups (Table 4 ). AlI the two-drug groups showed significantly greater inhibition of p24 production than their corresponding single-drug groups (P<O.01). However, combi-338 nation of 3 nM ZDV and 30 nM 3TC did not appear to be significantly more active than 3 nM ZDV alone (P>0.05) in our assay (Table 4) .
When these drug effects were subjected to further mathematical analysis, it was clear that combinations of two or three drugs were synergistic with CI<l at greater than 75% inhibition levels (Table 2) . Three-drug combinations ofZDV, DLV and 3TC were synergistic at 50,75,90 and 95% inhibition levels (Table 2) . Two-drug combinations ofDLV and 3TC were synergistic at 50,75 and 90% inhibition levels but appeared to be additive or moderately synergistic at 95% inhibition levels. The discrepancy in CI values between the studies was probably due to normal variations in biological assays. Combination of ZDV and DLV or ZDV and 3TC showed overall additive interactions at 50 and 75% inhibition but showed synergy at 90 and 95% inhibition levels ( Table 2) . None of the two and three-drug combinations tested showed any additive or synergistic cytotoxicity as determined by MIT assay (data not shown) at various drug concentrations (ZDVat 10 and 30 nM; DLV at 30 and 100 nM; 3TC at 100 and 300 nM). Therefore, the data indicated that the enhanced effects of the combinations were due to specific antiviral activities.
Discussion
The results of this study showed that combinations of DLV with 3TC or ZDV were moderately synergistic over a range of concentrations in HIV-1-infected PBMC culture. A synergistic antiviral effect in vitro has also been reported for two-drug combinations involving ZDV and several other NNRTls including DLV, pyridinone L-697,639 and nevirapine (Chong et al., 1994; Richman et al., 1991; Goldman et al., 1991) . Separately, Balzarini et al. (1996) reported that when combined with 3TC, several NNRTls, including DLV, more readily suppress viral 'breakthrough', and may delay the emergence of resistant virus. However, drug synergy between 3TC and the bisheteroarylpiperazine class of NNRTI (such as DLV) has not been reported. Our results suggested that the three-drug combination of DLV, 3TC and ZDV was moderately synergistic at inhibiting viral replication in PBMC cultures. We have previously reported that combinations of DLV, ZDV and ddI were also synergistic (Chong & Pagano, 1997) . However, we are not clear which of the combination regimens was more synergistic because very different drug combination ratios were used. Since ddI is about 10-fold less active than 3TC on a molar basis, similar combination ratios cannot be used in the two studies. In this study, combination ofDLV, 3TC and ZDV showed significantly greater suppression of viral growth than the two-drug combinations. Several on-going clinical trials have shown that combination of a NNRTI with one or more NRTls produced a greater improvement in clinical markers (Davey et al., 1996; Freimuth, 1996; D'Aquila et al., 1996; Staszewski et al., 1996) . However, unlike in vitro experiments, the enhanced efficacy of combination therapy in vivo is most likely owing to a combination of several factors, such as pharmacological synergy, the moderation of drug resistance mutations and viral fitness.
In addition to drug synergy, the combined use of a NNRTI with one or more NRTI has other potential benefits in terms of the differences in resistance profile and host factors required for drug action in vivo. Recent studies on viral resistance in vitro and in vivo have shown that NNRTls such as DLV do not share cross-resistance with NRTI such as 3TC and ZDV (Mellors et al., 1995; Arts & Wainberg, 1996) . It is known that most members of the NNRTls are highly specific inhibitors of the RT enzyme and show similar antiviral effects in many different cell types because they do not need cellular phosphorylation to produce their inhibitory effects (De Clercq, 1994a,b) . These properties may account for the finding that many NNRTls, including nevirapine and DLV, can completely suppress viral replication when used at high concentrations in cell cultures (Balzarini et al., 1993) . In contrast, NRTls such as 3TC and ZDV are competitive inhibitors and are dependent on host cell phosphorylation for their viral inhibitory effect. Thus, it is not surprising that ZDV has been found to be highly active in some cells types and yet shows only a weak antiviral effect in others (Peterson et al., 1994; Arts & Wainbel'g, 1996) . Although the clinical implication of this is not clear, it is likely that ZDV would be less active in certain host cells such as quiescent lymphocytes and macrophages. Antiviral Chemistry & Chemotherapy8 (4) Combination of DLV with 3TC and ZDV Another important finding of this study was that the combined use ofDLV, 3TC and ZDV did not show additive or synergistic toxicity to cultured PBMC at the highest drug concentrations evaluated (ZDV at 30 nM, DLV at 100 nM and 3TC at 300 nM). It should also be pointed out that the concentrations of the drugs used in' this study are much lower than the plasma concentration that can be achieved in patients (Davey et al., 1996) . Although our cell culture results provide a theoretical basis for beneficial therapeutic use ofDLV, 3TC and ZDV in combination, caution should be used in the extrapolation of in vitro findings to clinical situations, because the latter involve complex host factors. Recently, the Inter-Company Collaboration for AIDS Drug Development has formed a consensus master protocol for the evaluation of triple-drug combinations of antiretroviral agents that would facilitate such trials (Soo et al., 1995) . Since DLV acts synergistically with 3TC and ZDV in vitro, such a combination regimen should be evaluated in clinical trials.
